Q2 EPS Forecast for ORIC Pharmaceuticals Reduced by Analyst

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Research analysts at HC Wainwright dropped their Q2 2025 EPS estimates for shares of ORIC Pharmaceuticals in a research report issued on Monday, January 13th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.55) for the quarter, down from their prior forecast of ($0.54). HC Wainwright has a "Buy" rating and a $21.00 price target on the stock. The consensus estimate for ORIC Pharmaceuticals' current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for ORIC Pharmaceuticals' Q3 2025 earnings at ($0.57) EPS.

A number of other equities research analysts also recently commented on ORIC. Cantor Fitzgerald reissued an "overweight" rating on shares of ORIC Pharmaceuticals in a report on Tuesday. Wells Fargo & Company assumed coverage on shares of ORIC Pharmaceuticals in a research report on Thursday, October 31st. They set an "overweight" rating and a $20.00 target price on the stock. Finally, Wedbush reaffirmed an "outperform" rating and issued a $20.00 target price on shares of ORIC Pharmaceuticals in a report on Monday. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, ORIC Pharmaceuticals has an average rating of "Buy" and a consensus price target of $18.29.

ORIC Pharmaceuticals Trading Down 7.4 %

Shares of ORIC traded down $0.81 during mid-day trading on Thursday, hitting $10.07. The company's stock had a trading volume of 296,523 shares, compared to its average volume of 798,840. ORIC Pharmaceuticals has a 1-year low of $6.33 and a 1-year high of $16.65. The firm has a market capitalization of $710.29 million, a P/E ratio of -5.55 and a beta of 1.18. The firm has a 50-day simple moving average of $9.01 and a 200 day simple moving average of $9.46.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.01).

Hedge Funds Weigh In On ORIC Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of ORIC. JPMorgan Chase & Co. grew its stake in shares of ORIC Pharmaceuticals by 3.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 35,251 shares of the company's stock valued at $361,000 after buying an additional 1,279 shares during the period. Victory Capital Management Inc. grew its position in ORIC Pharmaceuticals by 4.1% during the third quarter. Victory Capital Management Inc. now owns 99,750 shares of the company's stock valued at $1,022,000 after acquiring an additional 3,900 shares during the period. Profund Advisors LLC raised its holdings in shares of ORIC Pharmaceuticals by 23.6% in the 2nd quarter. Profund Advisors LLC now owns 21,861 shares of the company's stock worth $155,000 after purchasing an additional 4,175 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of ORIC Pharmaceuticals by 71.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,568 shares of the company's stock worth $139,000 after purchasing an additional 5,646 shares during the period. Finally, Quest Partners LLC grew its holdings in shares of ORIC Pharmaceuticals by 253.2% during the 2nd quarter. Quest Partners LLC now owns 10,378 shares of the company's stock worth $73,000 after purchasing an additional 7,440 shares during the period. Institutional investors and hedge funds own 95.05% of the company's stock.

Insiders Place Their Bets

In other ORIC Pharmaceuticals news, CEO Jacob Chacko sold 24,660 shares of ORIC Pharmaceuticals stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $8.28, for a total value of $204,184.80. Following the completion of the sale, the chief executive officer now owns 778,648 shares in the company, valued at $6,447,205.44. The trade was a 3.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Pratik S. Multani sold 8,850 shares of the stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $8.28, for a total transaction of $73,278.00. Following the transaction, the insider now owns 46,765 shares in the company, valued at approximately $387,214.20. The trade was a 15.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 42,361 shares of company stock valued at $350,749. Corporate insiders own 5.55% of the company's stock.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.